You have full text access to this OnlineOpen article

ANTI-HSP60 and ANTI-HSP70 antibody levels and micro/ macrovascular complications in type 1 diabetes: the EURODIAB Study

  1. G. Gruden1,
  2. G. Bruno1,
  3. N. Chaturvedi2,
  4. D. Burt1,
  5. S. Pinach1,
  6. C. Schalkwijk3,
  7. C. D. Stehouwer3,
  8. D. R. Witte4,
  9. J. H. Fuller4,
  10. P. Cavallo-Perin1,
  11. EURODIAB Prospective Complications Study Group1

Article first published online: 8 MAY 2009

DOI: 10.1111/j.1365-2796.2009.02129.x

Issue

Journal of Internal Medicine

Journal of Internal Medicine

Volume 266, Issue 6, pages 527–536, December 2009

Additional Information

How to Cite

Gruden, G., Bruno, G., Chaturvedi, N., Burt, D., Pinach, S., Schalkwijk, C., Stehouwer, C. D., Witte, D. R., Fuller, J. H., Cavallo-Perin, P. and EURODIAB Prospective Complications Study Group (2009), ANTI-HSP60 and ANTI-HSP70 antibody levels and micro/ macrovascular complications in type 1 diabetes: the EURODIAB Study. Journal of Internal Medicine, 266: 527–536. doi: 10.1111/j.1365-2796.2009.02129.x

Author Information

  1. 1

    From the Department of Internal Medicine, University of Turin, Italy

  2. 2

    National Heart & Lung Institute, Imperial College, London, UK

  3. 3

    Department of Internal Medicine, University Hospital Maastricht, the Netherlands

  4. 4

    Department of Epidemiology and Public-Health, Royal Free and University College London, Medical School, UK

*Gabriella Gruden, Department of Internal Medicine, University of Turin, Corso AM Dogliotti 14, Turin, 10126, Italy. (fax: 0039 633 4751; e-mail: gabriella.gruden@unito.it).

Publication History

  1. Issue published online: 6 NOV 2009
  2. Article first published online: 8 MAY 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (137K)

Keywords:

  • atherosclerosis;
  • epidemiology;
  • HSP60;
  • HSP70;
  • microcirculation;
  • type 1 diabetes mellitus

Abstract.

Objectives.  The heat shock proteins 60 and 70 (HSP60, HSP70) play an important role in cytoprotection. Under stress conditions they are released into the circulation and elicit an immune response. Anti-HSP60 and anti-HSP70 antibody levels have been associated with cardiovascular disease. Type 1 diabetes is associated with a greatly increased risk of micro- and macrovascular complications. Therefore, we investigated whether anti-HSP60 and anti-HSP70 antibody levels were associated with micro- and macrovascular complications in type 1 diabetic patients.

Design.  A cross-sectional nested case-control study from the EURODIAB Study of 531 type 1 diabetic patients was performed.

Subjects.  Cases (n = 363) were defined as those with one or more complications of diabetes; control subjects (n = 168) were all those with no evidence of any complication. We measured anti-HSP60 and anti-HSP70 antibody levels and investigated their cross-sectional associations with diabetic complications.

Results.  Anti-HSP70 antibody levels were significantly greater in control than in case subjects, whereas anti-HSP60 antibody levels were similar in the two groups. In logistic regression analysis, anti-HSP70 levels in the upper quartiles were associated with a 47% reduced odds ratio of micro/macrovascular complications, independently of conventional risk factors, markers of inflammation and endothelial dysfunction [odds ratio(OR) = 0.53, 95% confidence intervals(CI): 0.28–1.02].

Conclusions.  In this large cohort of type 1 diabetic subjects, we found an independent and inverse association between serum anti-HSP70 antibody levels and diabetic micro/macrovascular complications. This suggests that anti-HSP70 antibody levels may be a novel marker of protection from chronic diabetic complications.

View Full Article (HTML) Get PDF (137K)